ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

Howard L. Kaufman, MD, FACS, has been appointed chief medical officer of Replimune Group Inc, a developer of oncolytic immunotherapies for the treatment of cancer. Kaufman has 25 years of leadership in academic oncology and is recognized as one of the leading physician scientists in the oncolytic immunotherapy field.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.